my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
11-09-2008: Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer on Innogenetics shares ran from 12 August to 5 September 2008.
After settlement of the offer, which is expected to be on 22 September, Solvay Group will hold 84.3% of the Innogenetics shares, the participation of 9.68% which Solvay held prior to the offer included. All conditions for the offer on Innogenetics have been met.
Solvay Pharmaceuticals has decided to reopen the offer from 23 September to 14 October 2008 in order to provide the remaining Innogenetics shareholders the opportunity to participate in this transaction.
The reference shareholders of Innogenetics (Rudi Mariën, Biovest CVA, Marigest Holding SA, S.A.T.E. SA and Gengest BVBA), who jointly hold 18.48% of the shares of the company, together with other institutional shareholders, have tendered their shares to Solvay.
“We are extremely pleased with the positive response of the Innogenetics shareholders”, said Werner Cautreels, CEO of Solvay Pharmaceuticals. “The reopening of the offer will provide the possibility for the remaining Innogenetics shareholders to take advantage of our offer. In the mean time, we will expedite the closing procedure of the transaction, in order to be able to implement rapidly our dual strategy : expansion of Innogenetics’ diagnostics business and leverage of both companies’ R&D competencies to accelerate the development of Solvay’s therapeutic pipeline through the implementation of biomarker, diagnostics and eventually companion diagnostics technologies”, he added.
Watchlist
This is where you can add this news to your personal favourites
Solvay Group holds 93.1% of Innogenetics shares
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group announced that it will acquire 2,714,371 additional shares of Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The shares were offered to Sol ... more
Solvay Pharmaceuticals acquires Innogenetics
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer on Innogenetics shares ran from 12 August ... more
Innogenetics announced that it has granted GlaxoSmithKline Biologicals (GSK) a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological human papillomavirus (HPV) vaccine studies. Innogenetics will receive royalties for each individu ... more
Innogenetics capitalizes on her expertise to provide diagnostic and therapeutic products that address pressing medical needs. Innogenetics operates a global specialty diagnostics business focusing on infectious diseases, genetic testing, and neurodegeneration. In parallel, Innogenetics stri ... more
Abbott to Acquire Solvay Pharmaceuticals Business
Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global em ... more
MediGene AG has signed a license and supply agreement with Solvay Arzneimittel GmbH, the German affiliate of Solvay Pharmaceuticals (Solvay) for the supply and commercialization of Veregen® (formerly Polyphenon E® ointment) in Germany, Austria, and Switzerland. Solvay's subsidiaries will pr ... more
H. Lundbeck A/S announced the joint decision with its partner Solvay Pharmaceuticals, B.V. to stop all joint R&D activities for Solvay's compound bifeprunox in development for maintenance treatment of schizophrenia. The companies made this decision after evaluating the recent results from ... more
It has always been the policy of the Solvay group to focus its efforts on product sectors where it has experience and know-how. The diversity of Solvay's activities is the result of systematic development of the by-products of each manufacturing process. This diversification centers on thre ... more
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic ... more
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic ... more
Abbott to Acquire Solvay Pharmaceuticals Business
Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global em ... more
MediGene AG has signed a license and supply agreement with Solvay Arzneimittel GmbH, the German affiliate of Solvay Pharmaceuticals (Solvay) for the supply and commercialization of Veregen® (formerly Polyphenon E® ointment) in Germany, Austria, and Switzerland. Solvay's subsidiaries will pr ... more
H. Lundbeck A/S announced the joint decision with its partner Solvay Pharmaceuticals, B.V. to stop all joint R&D activities for Solvay's compound bifeprunox in development for maintenance treatment of schizophrenia. The companies made this decision after evaluating the recent results from ... more
It has always been the policy of the Solvay group to focus its efforts on product sectors where it has experience and know-how. The diversity of Solvay's activities is the result of systematic development of the by-products of each manufacturing process. This diversification centers on thre ... more
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic ... more
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
